Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CARGO Therapeutics Enters into Agreement to Be Acquired by Concentra Biosciences for $4.379 in Cash per Share Plus a Contingent Value Right
-
CARGO Therapeutics Provides Corporate Update
-
CARGO Therapeutics to Discontinue FIRCE-1 Phase 2 Study of Firi-cel; Advances Remaining Programs While Evaluating Strategic Options
-
CARGO Therapeutics Provides Corporate Update and Anticipated Milestones for 2025
-
CARGO Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference
-
CARGO Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
-
CARGO Therapeutics to Participate in Upcoming Investor Conferences
-
CARGO Therapeutics Announces ASH 2024 Abstract on CRG-023, a Tri-specific CAR T, Highlighting Innovative Construct Design and Durable Anti-B-Cell Lymphoma
-
CARGO Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
-
CARGO Therapeutics Announces Phase 1 Clinical Study of Firi-cel CAR T-Cell Therapy Published in The Lancet